Trial Profile

Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Hodgkin's disease; Kaposi's sarcoma; Liver cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Skin cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

08 Aug 2024 Status changed from active, no longer recruiting to completed.
16 Jul 2024 Timeframe for primary measures changed from 'Up to 90 days after the last dose of trial treatment' to 'Up to 90 days after the last dose of trial treatment, up to 2 years or 35 cycles of trial treatment.'
24 Oct 2023 Results from the expanded Kaposi's-sarcoma cohort (n=32) presented at the 48th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com